13 January 2023 | News
To help people in need of effective migraine therapy
Theranica, a prescribed digital therapeutics company based in Israel developing advanced neuromodulation devices for migraine and other pain conditions, has announced a strategic license and supply agreement with Hyderabad-based Dr. Reddy's Laboratories, for the exclusive marketing and distribution of FDA-approved Nerivio in India, subject to completion of the regulatory approval process in India.
Under the terms of the agreement, Dr. Reddy's will be responsible for the regulatory approval of Nerivio in India, after which it will exclusively market Nerivio in India, manufactured and supplied by Theranica. The agreement includes licensing fees for exclusive rights to market Nerivio in India. While the agreement applies only to India, the companies will continue discussions about expanding to additional territories outside the United States and China.
Nerivio is the first US FDA-cleared, prescribed, digitally connected, drug-free wearable device for the acute treatment of episodic and chronic migraine in individuals age 12 and older. Worn on the upper arm, Nerivio utilises remote electrical neuromodulation (REN) to trigger an endogenous descending pain inhibition mechanism known as conditioned pain modulation (CPM), which aborts or alleviates migraine headache and associated migraine symptoms. Clinical studies have shown Nerivio to be as effective as standard of care pharmacological options for acute migraine treatment. The company recently published topline results of a pivotal trial demonstrating the efficacy and safety of Nerivio for the preventive treatment of migraine, an indication currently under FDA review.